Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.61 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | P4HB | P07237 | 1/20 | 0.56 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | F3 | P13726 | 1/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30383756 | 1.00 | KMT2A (1.00) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL25198797 | 0.92 | MEN1 (0.86) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL25195235 | 0.90 | MEN1 (0.82) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL25207663 | 0.89 | MEN1 (0.81) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL31233173 | 0.89 | MEN1 (0.81) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL31233297 | 0.89 | MEN1 (0.81) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL25193921 | 0.89 | MEN1 (0.81) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL25234254 | 0.89 | MEN1 (0.81) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL25223772 | 0.89 | MEN1 (0.81) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL30383816 | 0.89 | MEN1 (0.81) | KMT2AMEN1ALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | KMT2A 2792/4885MEN1 3367/4885ALDH1A1 3285/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | KMT2A 3188/4885MEN1 2457/4885ALDH1A1 3081/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | KMT2A 3188/4885MEN1 2457/4885ALDH1A1 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.